RM Primary Logo - Humble.png
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
26 févr. 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Bionano_RGB.png
American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis
22 févr. 2024 08h00 HE | Bionano Genomics
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of...
Vaccinex logo
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
21 févr. 2024 08h00 HE | Vaccinex, Inc.
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...
Turnstone Logo.jpg
Turnstone Biologics to Participate in Upcoming Investor Conferences
21 févr. 2024 06h00 HE | Turnstone Biologics Corp.
Turnstone to present and participate in TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024.
RM Primary Logo - Humble.png
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
20 févr. 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Nouveau Logo communiqué de presse.JPG
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
20 févr. 2024 07h30 HE | Theratechnologies
Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer...
Nouveau Logo communiqué de presse.JPG
Theratechnologies annonce la publication d’un article dans Frontiers in Immunology qui approfondit la compréhension du mécanisme d’action moléculaire du sudocétaxel zendusortide (TH1902)
20 févr. 2024 07h30 HE | Theratechnologies
MONTRÉAL, 20 févr. 2024 (GLOBE NEWSWIRE) -- L’article documente le déclenchement de la voie cGAS/STING, qui active des mécanismes de défense immunitaire et potentialise l’activité...
website-logo (2).png
Recombinant Proteins Market Predicted to Garner US$ 704.6 Bn By 2033, At CAGR 13.5% | Marketresearch.biz
20 févr. 2024 01h01 HE | MarketResearch.biz
New York, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The recombinant proteins market was valued at USD 205.0 billion in 2023 with significant growth and is projected to reach at USD 704.6 billion by 2033...
website-logo (2).png
Oncology Drugs Market to Surpass USD 332.4 Bn by 2033, Driven by Individualized Treatment | Marketresearch.biz Report
20 févr. 2024 00h53 HE | MarketResearch.biz
New York, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The oncology drugs market was valued at USD 176.6 billion in 2023 with a significant growth and is projected to reach at USD 332.4 billion by 2033 with an...
cmi_logo.png
[Latest] Global Roasted Coffee Market Size/Share Worth USD 73.46 Billion by 2032 at a 5.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 févr. 2024 12h30 HE | Custom Market Insights
Austin, TX, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Roasted Coffee Market Size, Trends and Insights By Type (Arabica, Robusta), By...